Ladiratuzumab vedotin

Generic Name: Ladiratuzumab vedotin

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1629760-29-7

Unique Ingredient Identifier: VM4G5D1A60

Background: Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Advances in ADCs: Opportunities for Treatment, Challenges, and Managing Toxicities

Antibody-drug conjugates (ADCs) are emerging in oncology, with dozens approved by the FDA. ADCs offer a 'bystander effect' but can increase off-target toxicity. Aditya Bardia highlighted ADCs like sacituzumab govitecan, trastuzumab deruxtecan, and datopotamab deruxtecan, which show superiority over chemotherapy in metastatic settings. Domenica Lorusso noted over 260 ADCs in cancer trials, calling them a 'rising star' in ovarian cancer. Toon Van Gorp emphasized TROP2 as a key target in cervical cancer. Challenges include understanding ADC resistance mechanisms and managing toxicities, necessitating multidisciplinary approaches.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.